ABEONA THERAPEUTICS INC. Fair Value Adjustment of Warrants
ABEONA THERAPEUTICS INC. (ABEO) reported Fair Value Adjustment of Warrants of $7.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $7.19M, a 33.46% increase year-over-year.
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$5.39M.
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$1.52M.
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$2.76M, a 118.21% decline year-over-year.
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2025 was -$6.14M, a 913.11% decline from fiscal 2024.
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2024 was $755.00K, a 93.54% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2023 was $11.70M.
- ABEONA THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2022 was -$11.38M.
| Period end | Fair Value Adjustment of Warrants | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.19M 10-Q · filed 2026-08-13 | $1.80M 10-Q · filed 2026-08-13 | $283.00K derived: sum of 3 quarters · filed 2026-08-13 | -$2.48M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$5.39M 10-Q · filed 2026-05-13 | -$6.91M derived: sum of 2 quarters · filed 2026-05-13 | -$9.67M derived: sum of 3 quarters · filed 2026-05-13 | -$4.28M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$4.28M derived: sum of 2 quarters · filed 2026-03-17 | $1.11M derived: sum of 3 quarters · filed 2026-08-13 | -$6.14M 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$2.76M 10-Q · filed 2025-11-12 | $2.63M derived: sum of 2 quarters · filed 2026-08-13 | -$4.62M 10-Q · filed 2025-11-12 | -$11.39M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-07-18 | $100.00K 10-Q · filed 2026-08-13 | ||||
| 2025-06-30 | $5.39M 10-Q · filed 2026-08-13 | -$1.86M 10-Q · filed 2026-08-13 | -$8.63M derived: sum of 3 quarters · filed 2026-08-13 | $6.52M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$7.25M 10-Q · filed 2026-05-13 | -$14.02M derived: sum of 2 quarters · filed 2026-05-13 | $1.14M derived: sum of 3 quarters · filed 2026-05-13 | -$23.79M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.38M derived: sum of 2 quarters · filed 2026-03-17 | -$16.55M derived: sum of 3 quarters · filed 2026-03-17 | $755.00K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $15.16M 10-Q · filed 2025-11-12 | -$9.77M derived: sum of 2 quarters · filed 2025-11-12 | $7.53M 10-Q · filed 2025-11-12 | $11.76M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$24.93M 10-Q · filed 2025-08-14 | -$7.63M 10-Q · filed 2025-08-14 | -$3.40M derived: sum of 3 quarters · filed 2025-08-14 | -$2.29M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $17.30M 10-Q · filed 2025-05-15 | $21.53M derived: sum of 2 quarters · filed 2025-05-15 | $22.63M derived: sum of 3 quarters · filed 2025-05-15 | $31.26M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $5.33M derived: sum of 2 quarters · filed 2025-03-20 | $13.96M derived: sum of 3 quarters · filed 2025-03-20 | $11.70M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $1.10M 10-Q · filed 2024-11-14 | $9.73M derived: sum of 2 quarters · filed 2024-11-14 | $7.46M 10-Q · filed 2024-11-14 | $2.08M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $8.63M 10-Q · filed 2024-08-12 | $6.36M 10-Q · filed 2024-08-12 | $976.00K derived: sum of 3 quarters · filed 2024-08-12 | -$2.07M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$2.27M 10-Q · filed 2024-05-15 | -$7.65M derived: sum of 2 quarters · filed 2024-05-15 | -$10.70M derived: sum of 3 quarters · filed 2024-05-15 | -$14.90M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$8.44M derived: sum of 2 quarters · filed 2024-03-18 | -$12.64M derived: sum of 3 quarters · filed 2024-03-18 | -$11.38M 10-K · filed 2024-03-18 | |
| 2022-09-30 | -$3.05M 10-Q · filed 2023-11-13 | -$7.25M derived: sum of 2 quarters · filed 2023-11-13 | -$6.00M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$4.20M 10-Q · filed 2023-08-08 | -$2.94M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $1.25M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |